Literature DB >> 15204243

Vascular insulin response is preserved in non-diabetic patients with coronary artery disease, despite endothelial dysfunction.

Nikolaj Ihlemann1, Christian Rask-Madsen, Lars Køber, Christian Torp-Pedersen.   

Abstract

BACKGROUND: Patients with coronary artery disease (CAD) are often insulin resistant, a state that predisposes to increased atherosclerosis. Recently, it was suggested that a "vascular insulin resistance" could explain this association, causing endothelial dysfunction and hence atherosclerosis. We therefore studied the vascular insulin response in patients with CAD.
MATERIALS AND METHODS: Nine non-diabetic patients with documented CAD and 31 lean healthy controls were examined. Forearm blood flow was measured by venous occlusion plethysmography. Dose-response studies of acetylcholine (ACh) and sodium nitroprusside (SNP) elicited endothelium-dependent and -independent vasodilation and were repeated during intra-arterial insulin infusion.
RESULTS: Patients were insulin resistant as determined by HOMA index. Insulin infusion resulted in high physiological levels of insulin in the forearm without systemic effects. Patients had a reduced ACh response but insulin infusion increased the ACh response equally in patients and controls (a mean increase of 74+/-37 vs 57+/-24%, patients vs controls, p=0.12). A minor increase of the SNP response was also noted during insulin infusion.
CONCLUSION: Vascular insulin response is intact in non-diabetic CAD patients in spite of insulin resistance and endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15204243     DOI: 10.1080/14017430310016397

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  1 in total

1.  Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease.

Authors:  Ahmet Var; Ozan Utük; Sinem Akçali; Tamer Sanlidağ; Bekir S Uyanik; Gönül Dinç
Journal:  Mol Biol Rep       Date:  2009-01-03       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.